Ventripoint Diagnostics Ltd.
(“Ventripoint” or the “Company”), (TSXV:VPT; OTC:VPTDF) is pleased to announce the Company has received official notification from OTC Markets to up-list to the OTCQB tier effective as of January 7, 2022.
The Company will trade on the OTCQB exchange under symbol “VPTDF”; the Company’s common shares will continue to trade on the Toronto Securities Venture Exchange under the symbol “VPT”.
Dr. George Adams, CEO, commented, “Trading on the OTCQB will enhance our visibility and make the Company accessible to a much broader range of U.S. investors and brokers. The quotation on the OTCQB will provide existing and potential investors with a transparent and easily accessible trading platform where they can find Real-Time quotes and market information.”
Shareholders of existing Ventripoint shares, previously quoted on the OTC® Pink Open Market, will now be quoted on the OTCQB without any further action required.
Investors can find current financial disclosure and Real-Time Level 2 quotes for the Company on www.otcmarkets.com.
The OTCQB is a US trading platform that is operated by the OTC Markets Group in New York. The OTCQB is the premier marketplace for entrepreneurial and development stage U.S. and international companies that are committed to providing a high-quality trading and information experience for their US investors. To be eligible, companies must be current in their financial reporting, pass a minimum bid price test, and undergo an annual company verification and management certification process.
The OTCQB quality standards provide a strong baseline of transparency, as well as the technology and regulation to improve the information and trading experience for investors.
The Company has also completed the application process for eligibility with the Depository Trust Company (“DTC”) and expects to have approvals shortly.
About Ventripoint Diagnostics Ltd.
Ventripoint has become an industry leader in the application of AI (Artificial Intelligence) to echocardiography. Ventripoint’s VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI.
This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients.
Providing better care to patients serves as a springboard and basic standard for all of Ventripoint’s products that guide our future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe and Canada.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.
This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words “expect”, “anticipate”, “continue”, “estimate”, “objective”, “ongoing”, “may”, “will”, “project”, “should”, “believe”, “plans”, “intends” and similar expressions are intended to identify forward-looking information or statements.
The forward-looking statements and information are based on certain key expectations and assumptions made by the Company.
Although the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Company can give no assurance that they will prove to be correct.
Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties.
Actual results could differ materially from those currently anticipated due to a number of factors and risks.
Factors which could materially affect such forward-looking information are described in the risk factors in the Company’s most recent annual management’s discussion and analysis that is available on the Company’s profile on SEDAR at www.sedar.com.
Readers are cautioned that the foregoing list of factors is not exhaustive. The forward- looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.
care of the redaction